10-K: NexGel Inc. Releases 2023 Annual Report, Highlights Growth and Strategic Initiatives

NexGel Inc.'s 2023 annual report reveals significant revenue growth, strategic acquisitions, and ongoing development in medical devices and consumer products.

Summary

• NexGel, Inc. reported a 99.7% increase in revenue for 2023, reaching $4.089 million, compared to $2.048 million in 2022.
• The company's gross profit increased to $619 thousand in 2023 from $256 thousand in 2022, with a gross profit margin of 15.1% in 2023 compared to 12.5% in 2022.
• Operating expenses totaled $4.096 million in 2023, up from $3.604 million in 2022, primarily due to increased selling, general, and administrative costs.
• The company experienced a net loss of $3.188 million in 2023, compared to a net loss of $4.746 million in 2022.
• NexGel acquired a 50% interest in a joint venture, CG Converting and Packaging, LLC, on March 1, 2023, contributing $500 thousand.
• The company also acquired the Kenkoderm skincare line in December 2023 for $546.5 thousand in cash, plus potential earn-out payments.
• Research and development expenses decreased to $103 thousand in 2023 from $367 thousand in 2022.
• As of December 31, 2023, NexGel had $2.7 million in cash and cash equivalents, compared to $1.101 million in 2022.
• The company completed a registered direct offering on February 15, 2024, raising approximately $1.025 million before expenses.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there is strong revenue growth and strategic initiatives, the company is still operating at a loss and faces significant risks. The recent capital raise is a positive sign, but the company's long-term success is not guaranteed.

Positives

• Significant revenue growth of 99.7% year-over-year indicates strong market demand for NexGel's products.
• Improved gross profit margin suggests better cost management and pricing strategies.
• Strategic acquisitions, such as Kenkoderm, expand the company's product portfolio and market reach.
• Development of medical devices like NEXDrape and NEXDerm presents opportunities for future growth and licensing.
• The company's manufacturing facility has significant unused capacity, allowing for rapid expansion to meet increased demand.
• The recent capital raise provides sufficient funds to operate the business into 2025.

Negatives

• The company experienced a net loss of $3.188 million in 2023, although this is an improvement from the $4.746 million loss in 2022.
• Operating expenses increased by 23.4%, primarily due to higher compensation, marketing, and professional fees.
• The company relies heavily on the Amazon marketplace for consumer product sales, which could be a risk if the relationship is disrupted.
• The company has no contracts with its customers, which could lead to revenue volatility.
• The company is dependent on a limited number of clients for a substantial percentage of its revenue.
• The company is reliant on two manufacturers for key ingredients used to manufacture of its hydrogels.

Risks

• The company's future success depends on market acceptance of its products, which may not be guaranteed.
• The company faces intense competition from larger, more established companies.
• The company's suppliers may fail to deliver components and raw materials on time or at acceptable prices.
• The company's reliance on a few major customers poses a risk to its revenue stream.
• The company's lack of contracts with customers could result in periods of low or no revenue.
• The company's products are subject to governmental regulations, and non-compliance could lead to penalties.
• The company's intellectual property may be infringed upon, which could harm its competitive position.
• The company has limited sales, marketing, and distribution capabilities, which could hinder growth.
• The company is exposed to product liability claims, which could result in significant expenses.
• The company's internal controls over financial reporting may not be able to detect fraud or other issues.
• The company's ability to attract and retain qualified personnel is critical to its success.
• The company's ability to pursue strategic partnerships may impact its ability to compete in the markets it serves or desires to enter.
• The company's stock price may fluctuate significantly, and an active trading market may not develop or be sustained.
• The company may not be able to pay dividends on its common stock.
• The company's principal stockholders, officers, and directors have the ability to control decisions with which other stockholders may disagree.
• The company is an emerging growth company and a smaller reporting company, which may make its common stock less attractive to investors.
• The company will incur costs as a result of operating as a public company, and its management will be required to devote substantial time to new compliance initiatives.
• Provisions in the company's charter and bylaws may prevent or delay an acquisition of the company, which could decrease the trading price of its common stock.
• The company's bylaws include a forum selection clause, which could limit its stockholders' ability to obtain a favorable judicial forum for disputes with the company.

Future Outlook

The company plans to maintain and grow its contract manufacturing business, develop its consumer product catalog, and explore drug delivery programs for its technology. Management is also evaluating strategic initiatives and additional capital raises.

Management Comments

• Management is exploring new product channel sales in consumer products, such as cosmetics, athletic products, and proprietary medical devices.
• The Company has increased its focus on sales and developing a sales pipeline for potential customers.
• We believe we have sufficient cash and marketable securities to operate our business plan into 2025.

Industry Context

The company operates in the competitive hydrogel manufacturing industry, facing competition from larger companies in the wound care, cosmetic, and drug delivery sectors. The company is also expanding into the consumer product and medical device sectors, which are also highly competitive.

Comparison to Industry Standards

• NexGel's revenue growth of 99.7% significantly exceeds the average growth rate for the medical device and consumer product industries, which typically range from 5% to 15% annually.
• The company's gross profit margin of 15.1% is lower than the industry average for medical device companies, which often exceeds 50%, but is comparable to some consumer product companies.
• The company's net loss, while improved from the previous year, is still a concern compared to established competitors who are typically profitable.
• NexGel's focus on electron beam technology for hydrogel manufacturing is a differentiator, as most competitors use chemical cross-linking agents.
• The company's development of medical devices like NEXDrape and NEXDerm is a strategic move to compete with established players like 3M Healthcare, but will require significant investment and partnerships to succeed.
• The company's reliance on Amazon for consumer product sales is a common strategy for smaller companies, but it also exposes them to risks associated with the platform.

Corporate Governance

Related Party Transactions

• Dr. Jerome Zeldis, a member of the Company board of directors, has an outstanding balance due of $ 25,000 for services as of December 31, 2023.

Stakeholder Impact

• Shareholders may be concerned about the company's continued net losses, but encouraged by the revenue growth and strategic initiatives.
• Employees may benefit from the company's growth and expansion, but may also face challenges related to the company's competitive environment.
• Customers may benefit from the company's innovative products and services, but may also be affected by any disruptions in the company's supply chain or operations.
• Suppliers may benefit from the company's increased demand for raw materials and components, but may also face risks related to the company's financial performance.
• Creditors may be concerned about the company's net losses, but encouraged by the company's recent capital raise and growth prospects.

Next Steps

• The company intends to maintain and grow its existing contract manufacturing business.
• The company plans to continue building and developing its catalog of consumer products.
• The company plans to develop its own proprietary medical devices and explore drug delivery programs.
• The company continues to evaluate strategic initiatives and additional capital raises.

Key Dates

Keywords

hydrogels, contract manufacturing, consumer products, medical devices, wound care, transdermal drug delivery, cosmetics, revenue growth, strategic acquisitions, joint venture, Kenkoderm, NEXDrape, NEXDerm, FDA, Amazon marketplace